Drug major Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), fulvestrant injection 250 mg/5 ml (50 mg/ml) per single-dose prefilled syringe.

The ANDA approved by the USFDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex injection, 250 mg/5 ml (50 mg/m) of AstraZeneca Pharmaceuticals LP.

Click for more articles on USFDA

Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of breast cancer.

According to IQVIA, fulvestrant injection has an estimated market size of USD 71 million for the twelve months ending September 2022.

The pharmaceutical company said that it has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from the USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

USFDA gives approval for this Genetic Disorder drug

USFDA gives approval for Lymphoma Therapy

USFDA gives approval for Pregabalin capsules

USFDA gives approval for Brivaracetam Tablets

USFDA approves Gene Therapy for Bladder Cance

USFDA approves this lung cancer drug

USFDA gives approval for this Genetic Disorder drug

USFDA changes Plan B label of Contraceptive Pills

Confession in criminal proceedings: Ground for conviction ?

USFDA gives approval for Lymphoma Therapy

PCI directs State Pharmacy Councils to expedite transfer of registration of Pharmacist

300 life-saving drugs needed from Indian Pharma Cos: Saudi Arab

Registration for sale of Medical Devices: Procedure and conditions

NPPA fixes Retail Price of 10 formulations: December 2022

Drug recall: This Blood Pressure tablets recalled

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/26/usfda-gives-approval-for-fulvestrant-injection/